MedTrace Logo

An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD

NCT03994328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1235

Last updated 2024-04-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate how safinamide, rasagiline and other SoC drugs are associated with the quality of life of PD patients by means of the Parkinson's Disease Questionnaire (PDQ)-39 items.

Conditions

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Zambon SpA

    lead INDUSTRY

Principal Investigators

  • Carlo Cattaneo · Zambon Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-03
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03994328 on ClinicalTrials.gov